Biological gates pass information while defences stop action
An in-cell poxvirus portal, an extinct smallpox lineage and rattlesnake serum proteins show the different boundaries of structural, historical and functional evidence.
Science··Morning
A three-protein gate in the poxvirus particle
A Francis Crick Institute team imaged the three-protein gate in a vaccinia virus particle inside the cell for the first time. Cryo-electron tomography was combined with AlphaFold2 structure prediction; the structure is linked to viral mRNA export and particle assembly. Vaccinia is a laboratory model for the poxvirus family. The researchers describe a possible drug target, but the result demonstrates neither a treatment nor clinical efficacy. The imaged channel is not merely an opening; the team describes it as a central hub linking core functions in the viral replication cycle. Export of messenger RNA made inside the particle and assembly of a new particle both touch the same structure. That dual role is attractive for drug research, but an apparently essential structure is not proof that it can be inhibited safely. Target validation will require separate cellular and organism-level experiments. Vaccinia, smallpox and mpox share a family without identical proteins, cell preferences or disease courses. A family-wide target requires measured conservation; structural similarity does not guarantee one drug effect.[1]
Chilean samples added an extinct lineage
Variola virus DNA was recovered from two people at the Camarones 9 site in northern Chile, dated between 1492 and 1631. The two near-identical genomes belong to an extinct branch that split after medieval European samples. The study reports roughly two centuries of slower evolution overlapping colonial expansion, followed by acceleration around the vaccination period; the researchers explicitly say that timing does not establish causation. The near identity of the two genomes supports the interpretation that the individuals may have been infected during the same outbreak. The branch splitting after medieval European samples shows that variola diversity in the Americas was not limited to one modern lineage. The period change in mutation rate is a statistical pattern not attributable to colonial movement or vaccination alone. Sample age, preservation and phylogenetic modelling remain integral to any ancient-DNA history. Two people open a valuable window without representing continental outbreak diversity. More genomes across time and place could constrain spread and disappearance, alongside preserved archaeological context.[2]
Serum defence is potent within a laboratory boundary
Combinations of conserved metalloproteinase inhibitors in rattlesnake blood were about ten times more potent than existing sheep-derived antivenom in vitro and protected against several viper venoms. The work covers only the metalloproteinase toxin family; other toxins need separate development and no human trial was conducted. The three findings do not describe one biological system: they constrain a molecular gate, a viral history and a specific toxin defence. The proteins were effective in specific combinations rather than individually, indicating complementary binding and inhibition routes. The combinations fully neutralised venom lethality in the laboratory, but that measurement does not include clinical conditions involving dose, distribution, immune response and treatment timing. The next path requires mixtures covering other toxin families, animal safety studies and only then human trials. Existing antivenom contains many antibodies, while this approach uses defined serum proteins. That may aid manufacturing consistency but raises immune and circulation questions; laboratory potency is not treatment dose.[3], [1], [2]
Related columns
For more information on this topic, you can read the related columns.
